Hepatitis C Pharmacogenetics: State of the Art in 2010

被引:125
作者
Afdhal, Nezam H. [1 ,2 ]
McHutchison, John G. [3 ]
Zeuzem, Stefan [5 ]
Mangia, Alessandra [6 ]
Pawlotsky, Jean-Michel [7 ]
Murray, Jeffrey S. [8 ]
Shianna, Kevin V. [4 ]
Tanaka, Yasuhito [9 ,10 ]
Thomas, David L. [11 ]
Booth, David R. [12 ]
Goldstein, David B. [4 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Gastroenterol & Hepatol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA 02215 USA
[3] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
[4] Duke Univ, Med Ctr, Ctr Human Genome Variat, Durham, NC USA
[5] JW Goethe Univ Hosp, Dept Internal Med, Frankfurt, Germany
[6] IRCCS Casa Sollievo Sofferenza, Div Gastroenterol, San Giovanni Rotondo, Italy
[7] Univ Paris EST, Hop Henri Mondor, Dept Virol, Creteil, France
[8] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[9] Nagoya City Univ, Dept Virol, Nagoya, Aichi, Japan
[10] Nagoya City Univ, Liver Unit, Nagoya, Aichi, Japan
[11] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA
[12] Univ Sydney, Westmead Millennium Inst, Sydney, NSW, Australia
关键词
PEGYLATED INTERFERON-ALPHA; GENETIC-VARIATION; IL28B POLYMORPHISM; RIBAVIRIN THERAPY; IFN-LAMBDA; GENOTYPE; PEGINTERFERON; EXPRESSION;
D O I
10.1002/hep.24052
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents. (HEPATOLOGY 2011;53:336-345)
引用
收藏
页码:336 / 345
页数:10
相关论文
empty
未找到相关数据